More Funds for Health Data Firm Temedica

Munich, Germany-based health insights company Temedica has raised EUR 42m in Series B funding, including a new EUR 25m extension. Money will be used to expand its range of solutions providing 'holistic insights into the care realities and journeys of millions of patients'.

Founded in 2016, Temedica GmbH extracts insights from anonymized health data from a range of sources and covering 'all' healthcare stakeholders. The firm combines a platform called Permea and a number of apps described as 'patient companions to promise 'a 360-degree understanding of patients' care realities', fully compliant with GDPR.

Analysis of more than 40 billion data points on over 50,000 diagnoses allows the company to provide insights on issues such as disease progression, treatment effectiveness, patient journeys and medication adherence. Sources include registry data, sales data for medically relevant products, insurance data, patient experience data and patient-generated data from the 'companion' apps. The firm says the results offer 'tangible added value' to patients, health care professionals, clinics, research institutions, pharmaceutical and biotechnology companies, and pharmacies. By channelling data back through the apps to patients, Temedica gives tens of thousands of patients 'an individualized understanding of their disease and how it relates to their lifestyle', enabling them to actively influence their condition.

Founder and CEO Gloria Seibert (pictured with co-founder Benjamin Friedrich) comments: 'Temedica's vision is to make a pioneering contribution to the development of personalized medicine by linking health-relevant data to new, evidence-based insights. We are convinced that big data sets and completely new types of data play a key role in this, such as patient-generated data from large populations outside of classic clinical trials. These enable a completely new knowledge and understanding of diseases and their actual courses. I am very pleased that our investors share this vision and accompany and support us as we continue to expand the Temedica ecosystem'.

The latest funding was led by existing investors MIG Capital and by a Munich-based family office, while earlier backers include the founding investors of BioNTech.

Web site: www.temedica.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.